Last checked at 27 Nov 2019 16:23
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown below:
Resolution | Votes For | Votes For (as % of votes cast) | Votes Against | Votes Against (as % of votes cast) | Votes Withheld |
1. Receive the Annual report and accounts for the Company | 22,673,789 | 100.0% | 0 | 0.00% | 515 |
2. Approve the Directors' Remuneration Report | 21,886,545 | 96.5% | 787,131 | 3.47% | 628 |
3. Re-appoint Tom Lindsay as a director | 22,674,304 | 100.0% | 0 | 0.00% | 0 |
4. Re-appoint Chris Yates as a director | 22,674,304 | 100.0% | 0 | 0.00% | 0 |
5. Re-appoint David Budd as a director | 22,674,304 | 100.0% | 0 | 0.00% | 0 |
6. Re-appoint Matthew Fowler as a director | 22,674,304 | 100.0% | 0 | 0.00% | 0 |
7. Re-appoint Ian Gilham as a director | 21,887,370 | 100.0% | 314 | 0.00% | 786,620 |
8. Appoint RSM UK as auditors of the Company | 22,674,304 | 100.0% | 0 | 0.00% | 0 |
9. Directors' authority to allot shares | 22,109,087 | 100.0% | 0 | 0.00% | 565,217 |
10. Disapplication of pre-emption rights | 19,551,681 | 88.4% | 2,556,891 | 11.57% | 565,732 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).
- Ends -
For further details please contact:
genedrive plc | www.genedriveplc.com |
David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 |
|
|
|
|
Peel Hunt LLP | +44 (0)20 7418 8900 |
James Steel / Oliver Jackson |
|
|
|
Stanford Capital Partners Limited | +44 (0)20 3815 8880 |
Patrick Claridge / John Howes |
|
|
|
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).